TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28781336

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS), twice a day, for three months
Number of subjects: 126

Group type: COMPARATOR
Intervention: Short-acting β2-adrenoreceptor agonist (SABA), inhalation only if necessary
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 126
Study: 25935057

Group type: COMPARATOR
Intervention: Systemic steroid and HBO (group 1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Intratympanic steroid (ITS) with systemic steroid and HBO (group 2)
Number of subjects: 58
Study: 23351408

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cod protein
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gluten
Number of subjects: 11

Group type: COMPARATOR
Intervention: Casein
Number of subjects: 11
Study: 21701791

Group type: COMPARATOR
Intervention: Griseofulvin (4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine (2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbinafine (4 weeks)
Number of subjects: 0
Study: 19155581

Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron, thiamine, riboflavin, folic acid, niacinamide, zinc and calcium (Group III)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron (Group II)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Vitamin A (Group I)
Number of subjects: 226
Study: 16449425

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) + Medication Adherence Training (MAT)
Number of subjects: 130

Group type: COMPARATOR
Intervention: MAT-Only
Number of subjects: 130
Study: 12818051

Group type: COMPARATOR
Intervention: Overlay technique
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Underlay technique
Number of subjects: 60
Study: 11009046

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9183592

Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation patients
Number of subjects: 27
Study: 8333006

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 15
Study: 3581104

Group type: EXPERIMENTAL
Intervention: Carmustine, hydroxyurea, and dacarbazine chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment and control arms
Number of subjects: 0
Study: 30316931

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention consisting of staff education and pamphlet and video decision aids (DAs)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) intervention
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Intervention group (SDM intervention)
Number of subjects: 182
Study: 26173655

Group type: EXPERIMENTAL
Intervention: Caffeine (6.0 mg/kg body mass)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 24118269

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) up to 180 mg/day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 54
Study: 22172429

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 4700

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Cost-effectiveness analysis
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Neurocognitive dysfunction
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Recurrence of angina
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Cardiovascular mortality
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Blood transfusions
Number of subjects: 4700

Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 4700
Study: 20954288

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2147

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 2147
Study: 18477661

Group type: EXPERIMENTAL
Intervention: rhGH and T (GHT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: rhGH (GH)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: T (testosterone)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15990759

Group type: EXPERIMENTAL
Intervention: Heart Failure Disease Management (DM) programs
Number of subjects: 5752

Group type: COMPARATOR
Intervention: Control (standard care or no DM)
Number of subjects: 5752
Study: 12800128

Group type: EXPERIMENTAL
Intervention: Hospital- and clinic-based smoking cessation interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral counseling and pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine implementation of smoking cessation methods
Number of subjects: 0
Study: 10569324

Group type: EXPERIMENTAL
Intervention: Quinapril
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal subjects (controls)
Number of subjects: 90
Study: 9162350

Group type: EXPERIMENTAL
Intervention: Sextant biopsy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Directed ultrasound guided biopsy
Number of subjects: 31
Study: 1853462

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (GaAlAs, 830 nm, continuous)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study: 6401928

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 4% ophthalmic solution
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30137410

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg (experiment DG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus saline infusion (experiment DS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline infusion (experiment D)
Number of subjects: 15
Study: 29609923

Group type: EXPERIMENTAL
Intervention: Fuzheng Jiedu Huayu Decoction (FJHD)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard treatment with placebo
Number of subjects: 284
Study: 27081185

Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB), n = 759
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Clopidogrel hydrogen sulfate (CHS), n = 798
Number of subjects: 1800
Study: 25011952

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 44
Study: 22047637

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy sessions with significant others present
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational Enhancement Therapy sessions without significant others (implied control)
Number of subjects: 0
Study: 19940323

Group type: EXPERIMENTAL
Intervention: Resistance-exercise program
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Flexibility-exercise program
Number of subjects: 32
Study: 17508971

Group type: EXPERIMENTAL
Intervention: HFA-BDP 100 microg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: CFC-BDP 200 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CFC-BDP 800 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast with HFA-BDP 400 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Montelukast with CFC-BDP 800 microg
Number of subjects: 0
Study: 15030959

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation for 8 weeks post discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study: 11311658

Group type: EXPERIMENTAL
Intervention: Taxanes (paclitaxel and docetaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxanes (paclitaxel and docetaxel) with concurrent radiotherapy
Number of subjects: 0
Study: 9797945

Group type: EXPERIMENTAL
Intervention: Visually perceived vertical (VPV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Visually perceived horizontal (VPH)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chair rotation speed of 2 degrees/s and 1/2 degree/s
Number of subjects: 8
Study: 8046313

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation with a target INR of 2.0-2.85
Number of subjects: 1124
Study: 2973188

Group type: EXPERIMENTAL
Intervention: 1.25 micrograms
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 0.625 micrograms
Number of subjects: 110

Group type: COMPARATOR
Intervention: 10 micrograms
Number of subjects: 110

Group type: COMPARATOR
Intervention: 5 micrograms
Number of subjects: 110

Group type: COMPARATOR
Intervention: 2.5 micrograms
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 110
Study: 30452479

Group type: EXPERIMENTAL
Intervention: Rumination induced condition
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 61
Study: 28207330

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 746

Group type: COMPARATOR
Intervention: Prevention as usual
Number of subjects: 746
Study: 26715479

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 µg (R2.5)
Number of subjects: 2784

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 µg (R5)
Number of subjects: 2784

Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 µg (HH18)
Number of subjects: 2784
Study: 23760946

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation (cognitive training plus reality orientation therapy)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Aspecific stimulation
Number of subjects: 9
Study: 22030225

Group type: COMPARATOR
Intervention: High-oleic sunflower oil (control)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Interesterified palm olein (IPO)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lard
Number of subjects: 50
Study: 19638785

Group type: EXPERIMENTAL
Intervention: Independent rater (IR) direct observation system for CVC insertion training
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Training module for IRs
Number of subjects: 38
Study: 16778461

Group type: EXPERIMENTAL
Intervention: Miconazole nitrate paste applied twice daily for 5 days at dosages of 1 and 2 mg/cm(2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Petrolatum and 15% zinc oxide pastes (without miconazole) applied twice daily for 5 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 15
Study: 15527668

Group type: EXPERIMENTAL
Intervention: Home exercise supplemented with an 8-week class-based exercise programme
Number of subjects: 214

Group type: COMPARATOR
Intervention: Home exercise
Number of subjects: 214
Study: 11259886

Group type: EXPERIMENTAL
Intervention: Warmed standard tracheal tube
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wire reinforced tracheal tube
Number of subjects: 50
Study: 9296232

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 1 mg/mL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 2 mg/mL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 4 mg/mL
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin 1 g at infusate concentrations of 5 mg/mL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8393581

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP; 600 micrograms/day) plus salbutamol (S; 900 micrograms/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salbutamol (S; 900 micrograms/day) alone
Number of subjects: 12
Study: 2947615

Group type: EXPERIMENTAL
Intervention: Buccal flap method (Rehrmann, 1936)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Palatal flap method (Ashley, 1939)
Number of subjects: 86
Study: 29466057

Group type: COMPARATOR
Intervention: Oral alendronate (ALN) 70 mg weekly
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 5 mg once yearly
Number of subjects: 161
Study: 27550619

Group type: EXPERIMENTAL
Intervention: HSC‐CM intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 25842457

Group type: EXPERIMENTAL
Intervention: Test gel (TG) - 5% sodium fluoride, 5% potassium oxalate, 10% strontium chloride
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fluoride gel (FG) - 2% sodium fluoride
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo gel (PG)
Number of subjects: 107
Study: 23034729

Group type: EXPERIMENTAL
Intervention: Ultrasound screening invitation (invited group)
Number of subjects: 67770

Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 67770

Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 67770

Group type: EXPERIMENTAL
Intervention: Screening invitation
Number of subjects: 67770
Study: 20653224

Group type: EXPERIMENTAL
Intervention: 3-D auditory cues present in dynamic environments
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3-D auditory cues present in static environments
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3-D auditory cues present
Number of subjects: 8

Group type: COMPARATOR
Intervention: 3-D auditory cues absent
Number of subjects: 8
Study: 17595194

Group type: EXPERIMENTAL
Intervention: Sibutramine plus weight management
Number of subjects: 10742

Group type: COMPARATOR
Intervention: Placebo plus standard care for weight management
Number of subjects: 10742
Study: 16293546

Group type: EXPERIMENTAL
Intervention: Intervention group received asthma kits (including peak flow meter, MDI spacer device, educational materials), training of health center staff in asthma care guidelines, and tools/templates for practice-level systems change.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group received only copies of the national asthma guidelines.
Number of subjects: 16
Study: 11980851

Group type: EXPERIMENTAL
Intervention: OBF pneumotonometer
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Tono-Pen
Number of subjects: 181

Group type: COMPARATOR
Intervention: Goldmann tonometer
Number of subjects: 181
Study: 10222609

Group type: EXPERIMENTAL
Intervention: Intensive education for five months (group lectures and individual counseling)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no intervention during the first five months)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall participants (n = 53)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Participants who successfully stopped smoking
Number of subjects: 53
Study: 7835571

Group type: EXPERIMENTAL
Intervention: 0.1N HCl
Number of subjects: 25

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 25

Group type: COMPARATOR
Intervention: Electrical stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Balloon stretch
Number of subjects: 25
Study: 2082483

Group type: EXPERIMENTAL
Intervention: 50 mg aspirin combined with 400 mg dipyridamole
Number of subjects: 249

Group type: COMPARATOR
Intervention: Standard anticoagulant therapy
Number of subjects: 249
Study: 34814

Group type: EXPERIMENTAL
Intervention: Floctafenine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30251330

Group type: EXPERIMENTAL
Intervention: 5 mg tadalafil
Number of subjects: 75

Group type: COMPARATOR
Intervention: 5 mg solifenacin
Number of subjects: 75
Study: 27871828

Group type: EXPERIMENTAL
Intervention: Voiding during catheterization
Number of subjects: 96
Study: 26438038

Group type: EXPERIMENTAL
Intervention: 0.12 % I‐C nasal spray, four times daily for four to ten days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo nasal spray (NaCl 0.5 %), four times daily for four to ten days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.12 % I‐C nasal spray
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo nasal spray (NaCl 0.5 %)
Number of subjects: 200
Study: 24279305

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day orally) added to regular antipsychotic medications for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (inactive compound identical in appearance to minocycline)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Minocycline (200 mg/day orally)
Number of subjects: 150
Study: 22081616

Group type: EXPERIMENTAL
Intervention: L. barbarum (120 ml)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L. barbarum (120 ml daily for 14 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 19822837

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and cognitive behavioral skills training (CBST) counseling intervention
Number of subjects: 1058
Study: 17542347

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study: 15880608

Group type: EXPERIMENTAL
Intervention: Combination treatment (peginterferon and lamivudine)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 95
Study: 14624818

Group type: EXPERIMENTAL
Intervention: Group comprehensive cognitive behavioral therapy (CCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (FLU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of FLU and PLA
Number of subjects: 0
Study: 10477209

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8723584

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (100 IU/kg or 300 IU/kg) administered daily by subcutaneous injection, commencing 10 days preoperatively and continuing until day 4 postoperatively (15 doses in total)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (100 IU/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (600 IU/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Epoetin alfa (any regimen)
Number of subjects: 200
Study: 2058823

Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg i.v. induction and 3-5 mg/kg per hour i.v. maintenance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg/kg i.v. induction and isoflurane 0.4-0.8 vol.% maintenance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Etomidate 0.2 mg/kg i.v. induction and flunitrazepam 0.005-0.01 mg/kg i.v. and fentanyl 0.0025-0.005 mg/kg i.v. bolus injections every 20-30 min maintenance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flunitrazepam/fentanyl maintenance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane and propofol maintenance
Number of subjects: 30
Study: 6286118

Group type: EXPERIMENTAL
Intervention: PIVN-associated chemotherapy (adriamycin, vincristine, VP16‐213 and cyclophosphamide) with 1550 kcal/day including 10% glucose, 20% lipids, and amino acids.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Chemotherapy control group (adriamycin, vincristine, VP16‐213 and cyclophosphamide) without PIVN.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PIVN-associated chemotherapy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Chemotherapy control group
Number of subjects: 19

Group type: COMPARATOR
Intervention: PIVN-associated chemotherapy and chemotherapy control group
Number of subjects: 19
Study: 31495192

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 30

Group type: COMPARATOR
Intervention: Compression garments
Number of subjects: 30
Study: 28728580

Group type: EXPERIMENTAL
Intervention: Restricted activity for 30 days post-surgery
Number of subjects: 210

Group type: COMPARATOR
Intervention: Unrestricted activity for 30 days post-surgery
Number of subjects: 210
Study: 26863464

Group type: EXPERIMENTAL
Intervention: Culturally and linguistically adapted physical activity print intervention for 6 months
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 196
Study: 23657665

Group type: EXPERIMENTAL
Intervention: nCPAP with humidification
Number of subjects: 31

Group type: COMPARATOR
Intervention: nCPAP without humidification
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: nCPAP with and without humidification
Number of subjects: 31
Study: 22966839

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (WBV) for 2 weeks, six 15-min sessions, 2 mm amplitude, 12 Hz frequency
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (WBV)
Number of subjects: 27
Study: 19524285

Group type: EXPERIMENTAL
Intervention: c-MYC amplification (defined as > or =2 copies c-MYC/CEP8)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Polysomy 8
Number of subjects: 97
Study: 17470020

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg daily for 6 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 15240605

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (4.1 mg/patch, twice a week; estimated delivery rate, 150 microg/d)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 12421172

Group type: EXPERIMENTAL
Intervention: Joel-Cohen incision
Number of subjects: 366

Group type: COMPARATOR
Intervention: Pfannenstiel incision
Number of subjects: 366
Study: 9615369

Group type: EXPERIMENTAL
Intervention: Ambulant chemotherapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Children younger than 10 years old
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Patients older than 17 years
Number of subjects: 53
Study: 8583218

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg/day for 8 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Albendazole 800 mg/day for 15 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Albendazole 800 mg/day for 30 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: High dose steroids
Number of subjects: 53

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 53